A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chronic Hepatitis C Infection
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Elbasvir; Grazoprevir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 22 Jun 2018 Planned End Date changed from 9 Apr 2020 to 17 Jun 2020.
- 22 Jun 2018 Planned primary completion date changed from 9 Apr 2020 to 25 Mar 2020.
- 23 Feb 2018 Planned End Date changed from 6 May 2020 to 9 Apr 2020.